➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: September 20, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,895,601

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,895,601 protect, and when does it expire?

Patent 8,895,601 protects BALVERSA and is included in one NDA.

This patent has sixty-one patent family members in thirty-six countries.

Summary for Patent: 8,895,601
Title:Pyrazolyl quinoxaline kinase inhibitors
Abstract: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer. ##STR00001##
Inventor(s): Saxty; Gordon (Cambridge, GB), Murray; Christopher William (Cambridge, GB), Berdini; Valerio (Cambridge, GB), Besong; Gilbert Ebai (Bad Duerkheim, DE), Hamlett; Christopher Charles Frederick (Cambridge, GB), Johnson; Christopher Norbert (Cambridge, GB), Woodhead; Steven John (San Diego, CA), Rees; David Charles (Cambridge, GB), Mevellec; Laurence Anne (Louviers, FR), Angibaud; Patrick Rene (Fontaine-Bellenger, FR), Freyne; Eddy Jean Edgard (Rumst, BE), Perera; Timothy Pietro Suren (Geel, BE), Gilissen; Ronaldus Arnodus Hendrika Joseph (Kasterlee, BE), Wroblowski; Berthold (Vosselaar, BE), Lacrampe; Jean Fernand Armand (Le Mesnil-Esnard, FR), Papanikos; Alexandra (Antwerp, BE), Querolle; Oliver Alexis Georges (Evreux, FR), Pasquier; Elisabeth Therese Jeanne (Le Neubourg, FR), Pilatte; Isabelle Noelle Constance (Louviers, FR), Bonnet; Pascal Ghislain Andre (Berchem, BE), Embrechts; Werner Constant Johan (Beerse, BE), Akkari; Rhalid (Vacquieres, FR), Meerpoel; Lieven (Beerse, BE)
Assignee: Astex Therapeutics Ltd (Cambridge, GB)
Application Number:13/643,741
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 8,895,601

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Janssen Biotech BALVERSA erdafitinib TABLET;ORAL 212018-001 Apr 12, 2019 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Janssen Biotech BALVERSA erdafitinib TABLET;ORAL 212018-002 Apr 12, 2019 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Janssen Biotech BALVERSA erdafitinib TABLET;ORAL 212018-003 Apr 12, 2019 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,895,601

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom1007286.6Apr 30, 2010
PCT Information
PCT FiledApril 28, 2011PCT Application Number:PCT/GB2011/050851
PCT Publication Date:November 03, 2011PCT Publication Number: WO2011/135376

International Family Members for US Patent 8,895,601

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 3210   Start Trial
Argentina 080982   Start Trial
Australia 2011247047   Start Trial
Australia 2017202512   Start Trial
Brazil 112012027509   Start Trial
Canada 2796204   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.